Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Atreca Inc BCEL

Alternate Symbol(s):  COLUF

Atreca, Inc. is a clinical-stage biopharmaceutical company. The Company is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. It is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.


PINL:BCEL - Post by User

Bullboard Posts
Post by sweatmanon Nov 24, 2013 12:45pm
454 Views
Post# 21935993

Yes, Rappy....

Yes, Rappy....


....I sure that those of us who are dispassionate players can (easily) see the future - especially when it comes to even *more* diution. Not sure what you are thinking, but I am figuring on a (at best) a five to one rollback. At worst, jettison most of the board and go for a clean ten to one rollback.  I know there are some who are agitating for an investigation, but with the size and stroke of the players involved on the finance end....I seriously doubt we will enjoy any such endeavour as the stench and splash-back would damage the entire sector and also weaken the trust factor of the entire system. I remember the days of Viola MacMillan and the huge Windfall scandal.

So when you say....'we all know what come next', allow me to assume you mean a rollback, what?

Bullboard Posts